RASD2 showed significant upregulation in thyroid cancer tissues, with elevated expression correlating with adverse clinicopathological parameters including lymphatic metastasis, extrathyroidal invasion, and advanced TNM stage. This evidence concerns the gene RASD2 and thyroid gland carcinoma.